Moderna's Surprise Profit: What It Means for MRNA

Moderna reported third-quarter revenue of $1.31 billion, up 29% year over year and far above the roughly $890 million analysts expected. The company earned $162 million, or $0.38 per share, compared with a $200 million loss in the same quarter last year. This was Moderna's first profitable quarter in two years, driven by strong international COVID-19 vaccine sales and a 27% reduction in research and development spending.

Management significantly raised its full-year revenue growth guidance to 15%-25%, up from up to 10%, and lowered its R&D budget to about $2.7 billion. Moderna now expects to end the year with $8.1 billion to $8.3 billion in cash, up from a prior forecast of $4.7 billion to $5.2 billion, including $2.6 billion raised from convertible notes and a $950 million litigation payment.

The main driver of investor enthusiasm remains intismeran autogene, a personalized cancer vaccine developed with Merck. In a Phase 3 melanoma trial, the combination with Keytruda reduced the risk of recurrence or death by 42% and cut the risk of distant spread by 38% compared with Keytruda alone. Moderna and Merck are working toward regulatory submissions.

Moderna's flu vaccine won FDA approval in August, and its combined flu and COVID-19 vaccine has been approved in Europe and Canada. The company is conducting a limited launch for the 2026-27 flu season, with a broader ramp expected next year.

Despite the good news, risks remain. International COVID-19 vaccine sales can be lumpy, U.S. approval for the flu/COVID combination is pending, and a Phase 3 norovirus vaccine trial did not meet early success criteria. After a roughly sevenfold gain this year, significant optimism is already reflected in the stock price.

For years, investors worried about Moderna's cash burn and ability to fund its pipeline without dilutive capital raises. The surprise profit and $8 billion cash pile largely alleviate those concerns, giving the company ample room to develop its pipeline on its own terms.

The raised guidance signals that management expects sustained growth, not just a one-time bump. Cost cuts are flowing through to the bottom line, and the company is demonstrating financial discipline while investing in key programs.

The cancer vaccine remains the biggest potential value driver. With Phase 3 data showing a 42% reduction in recurrence risk, the product could become a blockbuster if approved. The partnership with Merck adds credibility and commercial reach.

However, the stock's massive rally means expectations are high. Any delay or setback in regulatory submissions or future trial readouts could lead to sharp declines, as seen when detailed results leaked in October and the stock fell 17% in a day.

Investors will get more detail at Moderna's Analyst Day on Nov. 12, which could serve as a near-term catalyst or reality check.